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and twins
Donna M Werling1 and Daniel H Geschwind1,2,3,4,5*Abstract
Background: Autism spectrum disorders (ASDs) are more prevalent in males, suggesting a multiple threshold
liability model in which females are, on average, protected by sex-differential mechanisms. Under this model,
autistic females are predicted to carry a more penetrant risk variant load than males and to share this greater
genetic liability with their siblings. However, reported ASD recurrence rates have not demonstrated significantly
increased risk to siblings of affected girls. Here, we characterize recurrence patterns in multiplex families from the
Autism Genetics Resource Exchange (AGRE) to determine if risk in these families follows a female protective model.
Methods: We assess recurrence rates and quantitative traits in full siblings from 1,120 multiplex nuclear families and
concordance rates in 305 twin pairs from AGRE. We consider the first two affected children per family, and one
randomly selected autistic twin per pair, as probands. We then compare recurrence rates and phenotypes between
males and females and between twin pairs or families with at least one female proband (female-containing (FC))
versus those with only male probands (male-only (MO)).
Results: Among children born after two probands, we observe significantly higher recurrence in males (47.5%) than
in females (21.1%; relative risk, RR = 2.25; adjusted P = 6.22e−08) and in siblings of female (44.3%) versus siblings of
male probands (30.4%; RR = 1.46; adj. P = 0.036). This sex-differential recurrence is also robust in dizygotic twin pairs
(males = 61.5%, females = 19.1%; RR = 3.23; adj. P = 7.66e−09). Additionally, we find a significant negative relationship
between interbirth interval and ASD recurrence that is driven by children in MO families.
Conclusions: By classifying families as MO or FC using two probands instead of one, we observe significant
recurrence rate differences between families harboring sex-differential familial liability. However, a significant sex
difference in risk to children within FC families suggests that female protective mechanisms are still operative in
families carrying high genetic risk loads. Furthermore, the male-specific relationship between shorter interbirth
intervals and increased ASD risk is consistent with a potentially greater contribution from environmental factors in
males versus higher genetic risk in affected females and their families. Understanding the mechanisms driving these
sex-differential risk profiles will be useful for treatment development and prevention.
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Autism spectrum disorders are developmental disorders
that appear early in life and are defined by impairments
in social skills and language abilities, as well as restricted
interests and repetitive behaviors [1]. These symptoms
present heterogeneously, with some autistic children
showing severe intellectual disability and poor basic daily
living skills, and others with high intelligence and
capacity for independence. Overall, current prevalence
estimates for autism spectrum disorder (ASD) are ap-
proaching 1.5%, at 1 in 68 children, in the United States
[2], an increase that is thought to be attributed to in-
creased awareness among parents, physicians, and
teachers that leads to more frequent diagnoses. ASD
diagnoses are approximately four times more frequent in
males than in females, and the mechanisms responsible
for this sex difference are not well understood.
Genetic variation contributes strongly to ASD etiology,
as evidenced by high concordance rates between twins
[3,4] and high recurrence in siblings [5,6], as compared
with risk in the general population. ASDs also often ap-
pear sporadically as a result of deleterious de novo vari-
ants that arise in a parent’s germ line. The identification
of these rare, de novo copy number and single nucleotide
variants (CNV, SNV) in ASD cases from simplex fam-
ilies has proven especially fruitful for risk gene discovery
in recent years [7-14]. However, the heritable or familial
component of ASD’s genetic risk architecture, although
likely to account for more than 50% of genetic risk
[15,16], is still poorly understood; family-based genetic
linkage and association studies have identified very few
replicable risk loci [17-26].
Modeling patterns of inheritance have led to the pro-
posal that families with autistic children fall into two risk
classes for ASD: a majority of low-risk families in which
de novo variants are the primary genetic cause of ASD
and a minority of high-risk families in which inherited
variants follow a dominant transmission pattern for
males, with reduced penetrance in females [27,28]. Sib-
ling recurrence risk estimates from multiplex families
and from an infant sibling study fit this model, finding
ASD recurrence in close to 50% of later-born male chil-
dren in these families [6,28]. These studies report far
lower risk to later-born daughters from multiplex fam-
ilies (approximately 20%), consistent with the effects of a
biological mechanism that protects females from mani-
festing an ASD phenotype.
This model of relative resilience has been termed as
the female protective model, a variation on the multiple
threshold liability model for ASD risk [29]. According to
this model, genetic liability is distributed in the popula-
tion, and males and females have different thresholds, or
minimum variant loads, at which they present an ASD
phenotype [30,31]. Following from the model, one wouldexpect affected females to carry a greater risk variant
load than affected males on average, and that this variant
load, if inherited as opposed to de novo, should be
shared among siblings. This phenomenon of higher re-
currence risk to family members of the less frequently
affected sex is referred to as the ‘Carter effect’ [32]. Re-
cent evidence of higher scores on a quantitative measure
of autistic traits in siblings of female probands as com-
pared with siblings of male probands in two large,
population-based samples supports this hypothesis [33].
At the genetic level, earlier work also observed trends
toward higher rates of deleterious CNVs and SNVs
among autistic females [7-9,12-14]. A more recent study
found a significantly higher rate of CNV and SNV risk
variants in females with ASD and other neurodevelop-
mental disorders, as well as preferential transmission of
these CNVs from mothers [34]. However, most genetic
studies of rare variants have focused on collections of
sporadic ASD cases, which are assumed to show enrich-
ment for de novo mutation events (though it is likely
that inherited genetic variants contribute to risk among
these families as well). It is not known if the effects of
increased variant loads in females and their siblings are
also evident among multiplex families, which are as-
sumed be enriched for inherited risk variants, in the
population or in research collections such as the Autism
Genetics Resource Exchange (AGRE) cohort.
AGRE is a collection of pedigree and phenotypic data
and genetic material from families with autistic children
[35]. Due to an early focus on recruitment of families
with multiple affected children, AGRE families have
been widely utilized in genetic studies aiming to identify
shared, familial risk variants, including linkage analyses
[18,20-22,24-26] and family-based association testing
[17,23]. The female protective model predicts that
prioritizing families with affected females for variant dis-
covery work may enrich study samples for more deleteri-
ous and detectable variants with larger effect sizes than
the average familial risk variant load. Additionally, un-
derstanding the actions of female protective factors
could serve to identify new therapeutic avenues.
We analyzed recurrence and concordance patterns
in >1,000 multiplex families and >300 twin pairs from
the AGRE cohort to test two primary hypotheses based
on the female protective model: first, that males will
show higher rates of ASD than females, and second, that
risk will be greater for the siblings and co-twins of autis-
tic females than siblings and co-twins of autistic males.
We additionally posit several related, secondary hypoth-
eses. One is that sex-specific risk and/or protective fac-
tors and familial genetic risk variant loads contribute
simultaneously to individuals’ total liability for ASD [31],
such that: 1) even within families carrying high, female-
penetrant genetic liability, females will show lesser risk
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show higher risk than male siblings of exclusively male
probands. Finally, if we extend the concept of ASD
liability to include environmental risk factors, we
hypothesize that siblings of autistic males, who are pre-
dicted to carry relatively lesser familial genetic liability
than siblings of autistic females, will show a stronger re-
lationship between risk-associated environmental factors
and the likelihood of ASD diagnosis. If female-specific
factors protect against these environmental exposures
(as well as against genetic insults), then one can predict
that this association between environment and ASD risk
will be especially strong for the male siblings of autistic
females.
Methods
Subjects
AGRE is a collection of phenotypic and genetic data
from families with autistic children that was established
in 1997 [35,36]. Initially founded as a multiplex cohort,
AGRE currently also includes simplex families, though it
remains a valuable source of multiplex ASD families for
study. All subjects in AGRE provided written informed
consent or assent with parental agreement for behavioral
evaluation, blood sample collection, and the transfer of
collected data to the AGRE program. This study was ap-
proved by the Western Institutional Review Board
(AGRE), the Institutional Review Board at Washington
University (subject recruitment, principal investigator:
John Constantino), and by the Medical Institutional
Review Board 3 at the University of California, Los
Angeles.
Starting from the catalog of all AGRE subjects (data-
base queried on 14 April 2014), which included 12,260
individuals from 2,278 families, we filtered families for
inclusion in these analyses (Additional file 1: Figure S1).
Extended families were first parsed to nuclear families,
and in order to enrich this sample for cases with genetic
risk factors as opposed to environmental complications,
nuclear families that included a child with pre- or peri-
natal insults, or premature birth before 35 weeks, were
removed. Families with twin pairs or multiples of un-
known zygosity were also excluded.
For this study, we classified as affected all subjects
with study diagnoses of autism, ‘broad-spectrum, ’ or ‘not
quite autism’ based on a clinician’s evaluation of Autism
Diagnostic Interview-Revised and Autism Diagnosis Ob-
servation Schedule scores. A ‘broad-spectrum’ diagnosis
is given to individuals with pervasive developmental dis-
orders of varying severity and includes subjects with
conditions formerly termed as pervasive developmental
disorder-not otherwise specified (PDD-NOS) and Asper-
ger’s syndrome. A diagnosis of ‘not quite autism’ is given
to subjects who meet the autism cutoffs in all symptomdomains but who do not meet the age of onset criterion
or conversely who meet the age of onset criterion but
fall only one point short of autism cutoffs in one or
more symptom domains. Families with one or more chil-
dren with ambiguous diagnoses, in which AGRE clini-
cians did not evaluate a child but their parent reported a
diagnosis from a community professional, were removed
from the analysis. All monozygotic (MZ) multiples and
dizygotic (DZ) twin pairs from families meeting the
above criteria that included at least one affected child
were included in concordance analyses.
For analyses of siblings from multiplex families, we ap-
plied additional filters. First, since genetic risk variants
carried by MZ multiples are non-independent, we se-
lected one individual from MZ sets at random for inclu-
sion. Families with only one remaining affected child
were then excluded, as were families in which affected
children were half siblings of one another. The birth
order of all full sibling children was then assigned by
sorting the mother’s or father’s age at time of birth, if
known. For the 12 families who lacked parental age
information, birth order was assigned by sorting the
individual subject identification numbers, which are
assigned according to the birth order. The final multi-
plex sample consisted of 5,328 individuals from 1,120
nuclear families, including 2,404 affected children, 684
unaffected full siblings, and 2,240 parents.
Each multiplex nuclear family was then classified by
the sex of the first two affected children born in the fam-
ily (probands) either as FC with at least one affected
female proband or as MO with only affected male pro-
bands. While this approach will misclassify some fam-
ilies with later-born autistic daughters as ‘male-only,’ it
prevents the artifactual inflation of recurrence rates in
FC families (and deflation in MO families) that results
from calculating recurrence rates in the same, later-born
children that are also considered during family classifica-
tion. In other words, if the sex of all affected children in
a family is considered during family classification, then
later-born affected girls will always contribute positively
to the FC recurrence rate, while all female children in
MO families will be unaffected by definition, thus redu-
cing the apparent recurrence in MO families. Using the
sex of the first two affected children born to classify each
family therefore allows us to more definitively separate
MO from FC families than is possible from a single
proband but does not systematically bias the recurrence
rates that we observe in children born after the probands.
Sex ratios
We calculated the ratio of males to females from all af-
fected children in the multiplex family set. Then, since
previous studies have shown differences in the relative
numbers of affected males and females among high- and
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tios within the subsets of affected children who met the
criteria for the strict autism diagnosis, children with
lesser diagnoses of broad-spectrum or not quite autism,
children with a Vineland Adaptive Behavior Scales
(VABS) composite standard score within the top quartile
in the sample (score ≥75), and children with a VABS
score within the bottom quartile (score ≤50) [39]. We
applied the VABS as the main measure of interest here
as it is the most completely ascertained phenotypic
measure of intellectual ability or general functioning in
AGRE, with 1,656 of 2,404 (69%) cases with recorded
scores. Though we do utilize the full range of recorded
VABS scores for an additional assessment of quantitative
phenotypes, here, we simply use the top and bottom quar-
tiles of the VABS scores as a proxy for the most high- and
most low-functioning cases within this data set.
Recurrence risk
To determine if multiplex families from AGRE show evi-
dence of a female protective effect for ASD penetrance,
we assessed ASD prevalence in siblings beyond the two
affected children required per family to meet criteria for
multiplex status. We then tested whether this risk differs
by the sex of the evaluated children or by the families’
classification as MO or FC.
In all families with additional children born after their
second affected child, we assessed recurrence risk. First,
we recorded the affection status of all children born after
the second affected child (N = 456 children from 341
families); this provided the largest available sample of
latter-born children for estimating recurrence rates.
Next, we estimated recurrence in three variations of this
sample in order to give equal weight to each nuclear fam-
ily regardless of size and to directly replicate and extend
previous analyses of recurrence in the AGRE sample.
In the first variation, we recorded the affection status
of only the first child born after the second affected
(N = 341 families); this method ensures that all families
contribute independently to the risk calculation but
limits sample size. In the second variation, we replicated
the method applied in a 2007 study of recurrence risk in
AGRE families [28] by recording the affection status of
the third child from families with exactly three children
in which the first two children are affected with ASD
(N = 198 families). This strict approach was applied to
control for effects of ‘stoppage,’ or parents’ decisions to
curtail their intended family size after having children
with ASDs, on recurrence risk estimates. Here, for the
third variation, we also extended this strategy to test the
last-born child in all families who had only one add-
itional child after their second affected, regardless of the
total family size or birth order of the first two affected
children. This extension allowed us to include a greaternumber of families (N = 258 families) than that used in
the method from Zhao et al. [28] while still controlling
for potential stoppage effects.
To evaluate the risk across multiplex families without
limiting this analysis to later births in families who con-
tinued having children and without weighting these esti-
mates by including multiple children from large families,
we next calculated what we refer to as ‘familial risk.’ The
main purpose of this analysis was to determine whether
the patterns we observe in sample variations of latter-
born children are also reflected in the larger sample of
multiplex families from AGRE. In all families with at
least three children, we calculated ‘familial risk’ by run-
ning 1,000 trials in which two affected children are
masked at random and affection status is evaluated in a
third child. Per trial, the sexes of the masked affected are
also used to classify the family as FC or MO. Familial
risk is taken as the mean risk from these 1,000 randomi-
zations. This method allowed for the inclusion of those
families who stopped having children after their second
affected, as well as all children in each family regardless
of birth order. Since only one child per family was
considered in each randomized trial, this approach also
ensured that large families would not contribute dispro-
portionately to the risk estimate.
For each of these five estimates of recurrence or famil-
ial risk - (A) all subsequent children from all families,
(B) the single next-born child from each family, (C) the
third-born child from three-child families, (D) the last-
born child from families where the second affected child
is born second to last, and (E) familial risk from 1,000
random selections of one child per family - we per-
formed one-sided Fisher’s exact tests in JMP (SAS Insti-
tute, Inc., Cary, NC, USA) to compare the risk in males
to females and in FC to MO families. We also compared
the males’ and females’ risk within FC families and
males’ risk in FC to males’ risk in MO families. P values
were adjusted for these 20 tests by Bonferroni correc-
tion. Additionally, we applied logistic regression models
to test for interaction effects of sex by family type.
Birth order and interbirth interval
Earlier work has reported increased ASD risk for chil-
dren born shortly after elder siblings in population sam-
ples [40-42]. It is not known how a risk factor such as
short interbirth interval (IBI) interacts with genetic risk
profile. Additionally, though one might assume that risk
for ASD is constant across the births in a family who
share a common source of heritable genetic risk vari-
ation, it may be that risk for ASD is increased in later-
born children due to the additional accumulation of
deleterious variants in the germ line with increasing par-
ental age [43], for example. So, we investigated the rela-
tionships between birth order and IBI on recurrence risk
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ences in ASD recurrence rates for children born first
versus second after a family’s second affected child. Risk
was evaluated separately by subjects’ sex and family type,
and two-sided Fisher’s exact tests were applied to iden-
tify significant differences in risk between birth order
positions. For IBI, we used parents’ age at the time of
each child’s birth to calculate the number of months in
between siblings’ births. Using logistic regression for af-
fection status by the natural log of IBI in months, we
then tested the relationship between IBI and ASD risk
separately by sex and family type (MO or FC) in the
child born first after the second affected child from the
332 families with complete parental age information.
Maternal and paternal ages were considered as covari-
ates. Pregnancy and birth complications were not expli-
citly considered in this model, since all families with any
records of pre- or peri-natal insults or premature birth
before 35 weeks were excluded from this and all analyses
in this report.
Quantitative phenotypes
Previous studies have reported an exacerbation of the
male bias for ASD among high-functioning individuals
and a greater representation of females among cases with
intellectual disability [37,38,44,45]. In contrast, the female
protective model predicts that males, who lack female
protective factors, should be more severely impacted than
females by genetic risk loads of comparable magnitude;
this differential impact may be detectable as shifts in
phenotype severity, measured quantitatively. We tested
several quantitative phenotypes related to ASD severity
and intellectual ability, including the VABS composite
standard score [39] (1,656 recorded scores - 69% of cases),
the Peabody Picture Vocabulary Test (PPVT) standard
score [46] (1,386 recorded scores = 58% of cases), the Ra-
ven’s Progressive Matrices estimated non-verbal intelligence
quotient (Raven’s NVIQ) [47] (1,316 recorded scores =
55% of cases), and the Social Responsiveness Scale
(SRS) raw total score [48] (1,042 recorded scores = 43%
of cases), for sex differences overall and within FC fam-
ilies, and for differences between MO and FC families.
Affected subjects missing scores on these measures
were more likely to have been ascertained early on in
AGRE’s collection than more recently (as approximated
by the sequentially assigned ID number for each family;
difference in ID index between subjects with missing
versus recorded scores for VABS = −487.93, standard
error (std. err.) = 46.11, P < 1e−04; PPVT diff. = −385.96,
std. err. = 44.47, P < 1e−04; Raven’s NVIQ diff. = −282.98,
std. err. = 44.37, P < 1e−04; SRS diff. = −0.563, std. err. =
43.36, P = 0.99) and were also more likely to have been
born later in their family (difference in birth order between
subjects with missing versus recorded scores for VABS =0.047, std. err. = 0.043, P = 0.27; PPVT diff. = 0.24, std.
err. = 0.040, P < 1e−04; Raven’s NVIQ diff. = 0.24, std.
err. = 0.039, P < 1e−04; SRS diff. = 0.14, std. err. = 0.038,
P = 2e−04), than affected subjects with recorded scores.
We used scores as recorded by AGRE, and in cases
where a child was evaluated more than once, we used
the most recent score for analysis. All scores recorded as
‘untestable’ were set to missing. For the Raven’s NVIQ,
some children received scores of ‘ATN’ (above the high-
est possible NVIQ score normalized by age; N = 93) or
‘BTN’ (below the lowest possible NVIQ score normal-
ized by age; N = 19). These scores were recoded as 160
and 20, which are above the observed maximum and
below the observed minimum NVIQ scores in the
remaining subjects. These high and low values match
the maximum and minimum scores for the PPVT and
VABS standard scores, two metrics that are scaled analo-
gously to standard IQ.
Scores for the VABS, PPVT, and Raven’s NVIQ are
positively correlated with one another, with correlation
coefficients of 0.447 (VABS with Raven’s NVIQ), 0.545
(PPVT with Raven’s NVIQ), and 0.595 (VABS with
PPVT). As higher SRS scores indicate more severe ASD
traits, SRS is negatively correlated with the above mea-
sures (r = −0.291 with Raven’s NVIQ; r = −0.395 with
PPVT; r = −0.573 with VABS). However, each of these in-
struments measures a different aspect of abilities (adaptive
behavior, vocabulary ability, non-verbal intelligence) or
symptoms (traits specifically associated with the ASD
phenotype), and so, we opted to include all of these tests
in our analyses.
Sex and family classification comparisons were assessed
by t-tests allowing for unequal variances in JMP using the
scores from one proband selected at random from each
nuclear family. To test for phenotypic differences between
FC and MO families that are not potentially confounded
by potential sex differences in phenotypic measures, ran-
domly selected male probands were also compared. To
test for sex-differential phenotypes within FC families, a
paired t-test was used to compare scores from one ran-
domly selected affected female and one affected male
within each family. P values were adjusted for 16 tests by
Bonferroni correction.
Concordance in twin pairs
MZ (111 twin pairs and 1 set of quadruplets) and DZ
twins (193 pairs) with at least one affected member from
families without perinatal complications or ambiguous
diagnoses were evaluated for ASD concordance. MZ
multiples were stratified by their sex (female-female
(F-F) and male-male (M-M)) and tested for concordance
rate differences using the one-sided Fisher’s exact test
(F-F >M-M). For DZ twin pairs, we selected one affected
twin from each pair as the proband twin, and we
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sex of the co-twin and the sex of the proband (analogous
to FC versus MO comparison for siblings) using a one-
sided Fisher’s exact test (male co-twin > female co-twin
and female proband >male proband). We also used a lo-
gistic regression model to test for an interaction effect of
proband sex by co-twin sex on ASD recurrence rates in
this sample of DZ twins.
Results
Sex ratios
Within 1,120 nuclear families with two or more full sib-
ling children with diagnoses of ASD, there are 2,404 af-
fected children, including 1,867 affected males and 537
affected females for an overall male-to-female ratio in
these families of 3.48 (Table 1). In contrast with reports
of even greater male skew among less severely affected
cases [37], the sex ratio for children with AGRE diagno-
ses of broad-spectrum and NQA (‘not quite autism’) was
2.11, compared with 3.71 for children diagnosed with
autism. A comparison of sex bias within cases scoring in
the top and bottom quartiles from this sample on the
VABS, the most completely ascertained measure of gen-
eral functioning in the sample, showed a similar pattern,
with a greater proportion of affected females falling in
the high functioning quartile of the scale (M:F = 2.35)
than the lower functioning quartile (M:F = 4.05). We
note that these unexpected patterns may not accurately
reflect trends at the general population level and may in-
stead be a consequence of the multiplex ascertainment
scheme for AGRE.
Recurrence risk
The recurrence rate for ASD in the multiplex set of fam-
ilies with at least one child born after the second af-
fected (N = 456 children from 341 families) was 36.0%
(Additional file 2: Table S1A). The recurrence rate in
male children was 47.5% and 21.1% in female children, a
significant difference (P = 3.11e−09, adj. P = 6.22e−08),
representing a male to female (M:F) relative risk (RR) of
2.25 (Figure 1A); these sex-differential rates closely
match those observed by Zhao and colleagues analyzingTable 1 Ratio of affected males to females in multiplex famili
Number of
families
Number of affected
children
All diagnosesa 1,120 2,404
Autism 1,106 2,158
Spectrumb 220 246
Top quartile (≥75) VABSc 319 445
Bottom quartile (≤50)
VABSc
306 424
aAll diagnoses = autism, broad-spectrum, or not quite autism (NQA) study diagnose
composite standard scores for affected children from AGRE multiplex families. VABSa sample of 165 AGRE families [28]. We also observed a
difference in risk between FC and MO families, with
44.3% recurrence in FC and 30.4% recurrence in MO fam-
ilies (P = 1.78e−03, adj. P = 0.036) for a RR of 1.46 for FC
families compared with MO (Figure 1B). The sex differ-
ence in recurrence risk between males and females within
FC families was robust, with RR of 1.85 (P = 7.18e−04, adj.
P = 0.014), and the difference between males from FC
and MO families was nominally significant (RR = 1.27,
P = 0.043, adj. P = 0.86; Figure 1C). When only the first
child born after the second affected child was included
(N = 341 children), we find a RR of 2.36 in males com-
pared with females (P = 1.21e−08, adj. P = 2.42e−07) and
1.27 in FC compared with MO families (P = 0.051, adj.
P = 1; Additional file 2: Table S1B). Sex-differential risk
was again apparent within FC families, with RR of 2.07
(P = 7.19e−04, adj. P = 0.014).
Since parents’ decision to curtail their intended family
size after having an autistic child, or stoppage, impacts
analyses of family structure, we calculated recurrence
risk from 198 families with a specific structure: exactly
three full sibling children, with affected first and second
children, as was used to estimate recurrence rates in an
earlier study of AGRE families [28]. Recurrence risk pat-
terns in this specific set were comparable to those from
all families with additional births, with 38.9% risk over-
all, a RR of 2.39 in males versus females (P = 9.57e−06,
adj. P = 1.91e−04), RR of 2.31 in males versus females
from FC families (P = 1.86e−03, adj. P = 0.037), and a RR
of 1.46 in FC versus MO (P = 0.025, adj. P = 0.49;
Additional file 2: Table S1C). When this test is expanded
to consider all families who had only one more child
after their second affected (N = 258 families), recurrence
risk again follows the same pattern (M:F RR = 2.41,
P = 6.87e−07, adj. P = 1.37e−05; M:F in FC families
RR = 2.06, P = 3.59e−03, adj. P = 0.072; FC:MO RR =
1.43, P = 0.02, adj. P = 0.39; Additional file 2: Table S1D).
The difference between males from FC versus MO families
only reached nominal significance in the set of 198 families
with three children (RR = 1.44, P = 0.034, adj. P = 0.68).
We also calculated familial risk by applying a
randomization procedure that permitted inclusion of alles from AGRE
Number of affected
males
Number of affected
females
Male:
Female
1,867 537 3.48
1,700 458 3.71
167 79 2.11
312 133 2.35
340 84 4.05
s; bSpectrum = broad-spectrum or NQA; cVABS quartiles calculated from
, Vineland Adaptive Behavior Scales.
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Figure 1 Recurrence risk for ASD in multiplex families from AGRE by sex and family type. ASD risk to all children born first after the
second affected child in each family (N = 456 children from 341 families) is highest for males and in female-containing families. Mosaic plots
show the proportion of affected children by (A) sex, (B) family type as FC (female-containing) or MO (male-only), and by (C) sex within each
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95% confidence intervals around each recurrence rate estimate.
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the analysis. Familial risk in these families was found to
be 17.5% (Additional file 2: Table S1E), less than the
overall recurrence risk. This is likely a simple conse-
quence of including 221 families with unaffected, earlier-
born children; these families do not contribute to any
recurrence rate calculations. The absolute familial risk
estimates within each sex and family classification were
similarly low, at 25.56% for males and 9.79% for females
and 22.60% for FC and 14.37% for MO families. Relative
risks showed slightly more pronounced differences than
for recurrence risk (M:F RR = 2.61, P = 6.70e−07, adj.
P = 1.34e−05; FC:MO RR = 1.57, P = 9.72e−03, adj.
P = 0.19). Logistic regression for affection status in the
later-born children from each of the family sets de-
scribed above, or the non-masked, randomly selected
children from familial risk calculations, additionally
demonstrated significant main effects of sex and family
type on risk for ASD. However, in all family sets tested,
the interaction between sex and family type did not
reach significance (Additional file 2: Table S2).
Birth order and interbirth interval
When comparing recurrence risk by birth order, be-
tween children born two versus one births after the sec-
ond affected child, we find no significant differences inrisk to females overall and to children in FC families.
However, we observe that risk to males overall and risk
to children in MO families shows a trend toward a de-
crease from the first to the second post-affected child
(males: P = 0.042, adj. P = 0.33; MO: P = 0.028, adj.
P = 0.23; see Figure 2A,B). When children are stratified
by both sex and family type, we find that the risk to ei-
ther males or females from FC families does not differ
significantly between the first and second post-affected
children. In contrast, risk to males in MO families drops
for the second post-affected child, from 48.25% to 21.7%
(P = 0.022, adj. P = 0.18; Figure 2C). These patterns are
comparable when considering only the 83 families with
at least two children born after their second affected
child (Additional file 1: Figure S2A-C).
We also find a significant negative association between
the number of months since the birth of the second af-
fected child (IBI) and ASD risk to the next-born child
(X2 = 10.41, P = 1.25e−03; Table 2). Within subgroups of
children, this effect is significant for males overall
(P = 2.31e−04; Figure 3A), for children in MO families
(P = 6.63e−03; Figure 3B), and for male children in MO
families (P = 5.1e−04; Figure 3C). The relationship be-
tween IBI and ASD status does not reach significance
for any subgroup of females or children from FC fam-
ilies, consistent with the hypothesized existence of a
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fects MO families. However, when sex and family type
(FC or MO) are both included as factors in the regres-
sion model for recurrence, only the main effects sex and
IBI, not family type, are significant (Additional file 2:
Table S3). We also note that the significance of these ef-
fects appears to be driven by unaffected children withTable 2 Autism recurrence risk by interbirth interval
Group N Chi-squared P value Adjusted P value
All 332 10.41 1.25e−03 0.011*
Males 188 13.56 2.31e−04 2.08e−03*
Females 144 0.52 0.471 1
FC 129 2.7 0.100 0.903
MO 203 7.37 6.63e−03 0.060
FC, Males 75 1.69 0.194 1
FC, Fems 54 0.67 0.413 1
MO, Males 113 12.08 5.10e−04 4.59e−03*
MO, Fems 90 0.049 0.825 1
Chi-squared statistics and P values are from the whole-model test for logistic
regression of affection status of the first child born after the second affected
child by the natural log of the interbirth interval (time since the birth of
the second affected child) in months. Adjusted P values have been
corrected for nine tests. *Adjusted P value ≤0.05. MO, male-only families;
FC, female-containing families.long IBIs (Figure 3D,E); when we evaluate only those
children born within 60 months of the second affected
in their family, the associations between IBI and ASD
risk diminish (males P = 0.05, females P = 0.600, FC
P = 0.6, MO P = 0.4).
Quantitative phenotypes
To determine if males and females or the different fam-
ily types differed from one another in the presentation
of ASD and its impact on functioning, we assessed
quantitative measures of ASD severity, general function-
ing, and intellectual ability. To compensate for the non-
independence of multiple children from each family, we
compared VABS, PPVT, Raven NVIQ, and SRS scores
from one randomly selected proband per family. We ob-
served significantly higher VABS (better adaptive func-
tion) scores in probands from FC compared with MO
families (average FC-MO difference = 4.42, P = 2.60e−03,
adj. P = 0.042). This difference was also nominally sig-
nificant when comparing only male probands (FC-MO
difference = 2.85, P = 0.049). We also observed signifi-
cantly lower VABS scores in males from FC families as
compared with their sisters by a paired test (average dif-
ference = −2.85, P = 0.035). No comparison of scores
from the PPVT, Raven’s NVIQ, and SRS showed any sig-
nificant group differences on these measures.
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We assessed concordance rates in 112 MZ multiples and
193 DZ twin pairs from AGRE. We identified high con-
cordance rates in MZ multiples with male pairs (M-M)
showing 95.6% concordance and female pairs (F-F) show-
ing 85% concordance (F-F:M-M RR = 0.89, P = 0.11;
Figure 4A; Additional file 2: Table S4A). For DZ twin
pairs, we find a significantly higher recurrence rate among
male co-twins than female co-twins (61.5% versus 19.1%;
M:F RR = 3.23, P = 1.92e−09, adj. P = 7.66e−09; Figure 4B;
Additional file 2: Table S4B); this sex difference is also ap-
parent when co-twins of female probands are tested separ-
ately (71.4% versus 20.0%; M:F RR = 3.57, P = 2.97e−03,
adj. P = 0.012; Figure 4D; Additional file 2: Table S4B). We
also observe a trend toward higher recurrence rate in co-
twins of female probands than male probands (50.0%
versus 41.4%; F-pro:M-pro RR = 1.21, P = 0.23; Figure 4C;
Additional file 2: Table S4B). Logistic regression for co-
twin affection status corroborated these results bydemonstrating only a significant main effect of co-twin
sex (P = 3.45e−06); neither the proband sex nor the inter-
action (proband sex by co-twin sex) terms were significant
in this model (Additional file 2: Table S4C).
Discussion
The first main hypothesis derived from the female pro-
tective model is simply that males should demonstrate
greater ASD risk than females. Our findings confirm this
prediction, as we observe 2.25- to 2.6-fold increased re-
currence risk to males compared with females. This in-
creased risk for ASD in males compared with females
corroborates findings from other studies of recurrence
risk in infant siblings [6] as well as in a sample of fam-
ilies from AGRE and the Interactive Autism Network
registry [5]. The observed recurrence rates of approxi-
mately 50% in males and 20% in females are also entirely
consistent with those reported by Zhao et al. [28], whose
earlier analysis also utilized a smaller sample of AGRE
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rates in DZ twins confirm this hypothesis as well, with
male co-twins showing a 3.23-fold increased risk com-
pared with female co-twins.
The second primary hypothesis from the female pro-
tective model is that the siblings of female probands
should demonstrate greater ASD risk than the siblings
of male probands, which we observe. We note that onlywhen all children born after the second affected child
are included in the recurrence rate calculation does this
comparison survive a conservative correction for mul-
tiple testing. In other family structures (last child from
three-child families, last child from families of three or
more, familial risk estimation), where only one child per
family is permitted to contribute to the recurrence risk
estimate, the differences between FC and MO families
Werling and Geschwind Molecular Autism  (2015) 6:27 Page 11 of 14no longer reach significance. These shifts in statistical
significance between family sets utilizing one or more
later-born affected children in the recurrence risk esti-
mate suggest that this analysis is likely to be underpow-
ered. The findings from the analysis of 193 DZ twin
pairs suggest a similar issue, as DZ twin pairs show a
non-significant trend toward higher recurrence risk in
co-twins of female than of male probands.
We also acknowledge that the maximum magnitude of
the Carter effect that we are able to observe in these
data is limited by our stratification approach, which con-
siders the sex of only two, early-born probands per fam-
ily, or one proband twin per twin pair. We apply this
approach to avoid systematic increases in risk estimates
for FC families and twins that result from using the
same children to both stratify families and to calculate
family-stratified recurrence rates. By the proband-based
approach that we use, families that are found to carry
female-penetrant risk loads post hoc, as evidenced by af-
fected, later-born female children or affected female co-
twins, may be grouped with families and twin pairs of
exclusively male affected children for analysis. If these
‘misclassified’ families and twin pairs carry the sorts of
high genetic risk loads that are responsible for the Carter
effect, this will increase recurrence rate estimates among
‘MO’ families and attenuate the observable difference
between FC and MO families and twins. Therefore, the
observation of higher recurrence in imperfectly sepa-
rated FC families or twins compared with MO that over-
comes this counter-hypothetical skew introduced by our
method can be interpreted as robust evidence of the
Carter effect.
Our secondary hypotheses address the relationship be-
tween subject sex and familial genetic risk load. We pre-
dicted that females from FC families should show
reduced risk compared with males from these same fam-
ilies, which is observed. Recurrence rates in later-born
female children from FC families are significantly lower
than for male children from these families and are also
reduced in female co-twins of female probands, demon-
strating the impact of female-protective mechanisms
even within highly risk-loaded FC families and twins.
The observation of a consistent direction of recurrence
rate differences between FC and MO males and the dif-
ferences that we observe when both sexes are considered
suggest that the lack of a significant difference among
males from different family types is likely to be a conse-
quence of low power within this subset of samples. Ana-
lysis of multiplex families from other, larger collections will
be necessary to conclusively reject the null for the impact
of sex-differential familial liability on ASD risk in males.
Alternatively, the lack of a significant increase in risk
to FC males over MO males may suggest a potential
modification to the multiple threshold liability model.As opposed to conceptualizing genetic risk load severity
as purely quantitative, there may be a locus-specific
component such that females are only vulnerable to the
effects of a subset of specific inherited risk variants that
uniformly increase males’ risk. Risk variants may be
assigned to one of the two classes: 1) variants that are
penetrant in both males and females and 2) variants that
are predominantly penetrant in males. These variant
classes may be functionally delineated by the specific loci
that harbor the risk variants, in that some loci increase
ASD risk in both sexes (relative to sex-differential, base-
line population risk) but females are nearly fully pro-
tected from variants at other loci. There are a handful of
risk loci such as SHANK1 microdeletions [49] and
16p13.11 CNVs [50] that have been reported to follow
such a pattern, where male carriers manifest ASD or
other neurodevelopmental conditions and female car-
riers do not.
Of the four quantitative phenotypic measures of intel-
lectual ability tested and for all comparisons of interest,
only the VABS showed post-correction and nominally
significant score differences. In agreement with our hy-
potheses, paired tests comparing VABS scores in male
versus female siblings from FC families show nominally
lower scores in brothers compared with their sisters,
consistent with the prediction that males would be more
severely impacted by female-penetrant risk loads. These
data suggest that genetic and sex-differential risk loads
in these families impact liability for the ASD phenotype,
but that they have minimal to no consistent impact on
the measureable degree of symptom severity, intellectual
ability, or adaptive functioning.
Lastly, we posited that siblings of autistic males should
show a stronger contribution from non-genetic, environ-
mental risk factors on their liability for ASD than sib-
lings of autistic females, whose risk is predicted to be
more completely derived from a larger genetic liability.
The finding that IBI is a significant predictor of ASD re-
currence risk supports this hypothesis. In agreement
with previous studies of population-based cohorts from
California [40,42] and Norway [41], we observe a nega-
tive relationship between IBI and ASD risk, with no aut-
istic cases born more than 75 months after their next
eldest, autistic sibling and with children born after short
IBIs showing the highest recurrence rates. We find that
IBI is a significant predictor of affection status only for
males, specifically those born into MO families. This
finding is consistent with the idea of males as more vul-
nerable to risk factors in general, as well as with our hy-
pothesis that lesser variant loads in MO families may
leave room for contributions from non-genetic risk fac-
tors. Such non-genetic factors may include events in
uterine or early postnatal development; maternal stress,
inflammation, and deficiency of micronutrients such as
Werling and Geschwind Molecular Autism  (2015) 6:27 Page 12 of 14folic acid have all been hypothesized as potential causes
of the increased risk for ASD in children born after
short IBIs [41,42,51]. Discordance patterns in DZ twins
are also consistent with this concept of non-heritable
risk factors from which females are protected, as female
DZ twins are far less likely to be affected with ASD than
their male co-twins. Currently, the roles of these pro-
posed factors in ASD risk remain speculative. Future
work is needed to definitively identify the potential ma-
ternal factors involved.
Previous studies report recurrence risks of 10% to 20%
overall, far lower than observed here. These lower fre-
quencies can most likely be attributed to the joint con-
sideration of families with both inherited and de novo
genetic risk architecture, as approximated by multiplex
and simplex family structures, respectively. Supporting
this, study of high-risk infant siblings reported greater
recurrence risk in the subset of families with two or
more elder affected of 32.2% overall and nearly 50% in
males [6]; these rates are entirely consistent with what
we observe here in AGRE.
Additionally, several studies of larger samples and
population-based cohorts have tested and failed to ob-
serve a significant effect of older affected siblings’ sex on
risk to later-born children [5,6,52,53]. One major differ-
ence between these study designs and that applied here
is that we utilize two probands per family to classify
families as FC or MO. By considering a greater number
of affected children from each family, we are able to
achieve a cleaner delineation between families with
female-penetrant and male-specific risk loads. Also, the
birth of an affected female child at any time in a family’s
pedigree (or here within the first two affected, for meth-
odological reasons) serves as a positive indicator of a
high familial liability load that is likely to have a larger
effect size as compared with the heritable variants car-
ried by MO families on average. Therefore, genetic stud-
ies that focus on FC families may have increased power
to detect and implicate heritable risk variants, which
have so far remained largely elusive.
Previous work has reported closer to equal representa-
tion of autistic males and females among severely im-
pacted cases with comorbid intellectual disability and a
more pronounced male bias among high-functioning
individuals [37,38]. We observe the opposite pattern,
which may be characteristic of multiplex families or spe-
cific to AGRE. With regard to the reports from other
samples on sex ratios in high- and low-functioning indi-
viduals, it has been suggested that current diagnostic
tools are calibrated to a male-typical phenotype and that
females are under-diagnosed for ASD due to their non-
prototypical presentation of ASD symptoms [54,55]. For
females who lack comorbid intellectual disability, diag-
noses may be especially elusive. However, in this AGREsample, the increased number of higher-functioning fe-
males may be a consequence of the ascertainment of
families with multiple diagnosed children, and/or it may
be that parents with an autistic child are more percep-
tive of symptoms in their daughters regardless of her in-
tellectual ability.
The increased number of diagnosed females relative to
males in this sample as compared with the general
population (male/female relative risk of approximately
2.25 versus 4.5 in population samples from the United
States [2]) may also be a consequence of an increased
sensitivity to females’ symptoms. Findings from studies
that are designed to evaluate all female and male sub-
jects equivalently (as opposed to analyzing existing diag-
nostic records) support this possibility, including recent
epidemiological population screens (South Korea, M:F =
2.5:1 [56]; Finland, M:F = 2:1 [57]) and a study of infant
siblings of autistic probands (M:F = 1.65:1 [58]). It is also
possible that male, latter-born children in multiple inci-
dence families have less ASD risk, or that females have
greater ASD risk, than their earlier-born siblings and
that this change drives the attenuated relative risk that
we observe in our sample. Here, we do observe a decline
in male children’s recurrence rates between the first and
second births after a second affected child (but no
change in female children’s recurrence), consistent with
such a sex-differential birth order effect on risk. Though
here, this birth order effect was only a trend and thus
warrants further investigation.
We also comment that the burden of care required by
an autistic child can be substantial, and so, in addition
to potential differences at the genetic risk level, there
may be key differences between those parents who con-
tinue to have children after their earlier-born child is di-
agnosed with ASD and parents who do not. Though
they may carry highly penetrant, heritable risk variants,
the latter families will appear as simplex and are there-
fore not characterized here. A comparison of quantita-
tive phenotypic measures in families who stopped versus
continued having children after their second affected
child does show trends of lower VABS scores in families
who stopped, though these differences do not reach
significance after adjustment for multiple testing
(Additional file 2: Table S6).
Conclusions
We characterize recurrence risk in a large cohort of uni-
formly ascertained multiplex families and observe sig-
nificant sex differences in recurrence rates, with females
showing a greater than twofold reduction in risk com-
pared with males’ risk. We also observe higher recur-
rence rates in families with at least one affected female
proband as compared with families whose probands are
exclusively male; this difference is expected under the
Werling and Geschwind Molecular Autism  (2015) 6:27 Page 13 of 14sex-differential threshold liability model for ASD. We
further report a significant relationship between ASD
and interbirth interval that is driven by male siblings of
male probands. Taken together, these observations dem-
onstrate that sex, genetic risk load, and putative environ-
mental exposures all contribute to liability for ASD and
that families with autistic females comprise a set of
multiplex families enriched for larger genetic risk variant
loads. Identification of female protective mechanisms in
these high-risk families would open up new therapeutic
windows, and the work to discover sex-differential herit-
able risk variant loads will advance our understanding of
the shared familial component of ASD risk.
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